<DOC>
	<DOCNO>NCT02074163</DOCNO>
	<brief_summary>Botox act nerve ending , yet nerve ending inside muscle , typically inject . All nerve terminate fascia , ASIS device precisely deliver Botox create subdermal bloodless space , skin muscle . Thus enhance prolong Botox 's efficacy , time prevent 's unnecessary adverse reaction distant spread , especially since Botox reason travel rest body way .</brief_summary>
	<brief_title>ASIS Botox Chronic Migraine</brief_title>
	<detailed_description>Aim 1 6 month demonstrate ASIS device 's consistent performance 60 adult subject Chronic Migraine ( â‰¥15 day per month , headache last 4 hour day longer ) . Gadolinium inject ASIS subdermally ( 30 ) conventional intramuscularly ( 30 ) 6 muscle group : Glabella , Frontal , Temporal , Occipital , Paraspinal , Trapezius . An MRI take promptly Gadolinium injection , start reference , subsequent MRI take 6 hr , 12 hr , 24 hr later compare Persistent % . Since n't way measure level Gadolinium within , ( e.g . Botox ) matter , least Prolongation Gadolinium may approximate great longer Persistent % MRI . However , approximation work variable minimize population Chronic Migraine , particular 6 muscle group . Case point , patient Chronic Migraine presumably hyperactive Glabella , Frontal , Temporal , Occipital , Paraspinal , Trapezius muscle , expectantly shorten Gadolinium intramuscularly Persistent % , somewhat Gadolinium subdermally Persistent % well due agitation , thus Persistent % value Chronic Migraine patient like normal patient , even 6 different muscle group . Therefore , Relative Prolongation Ability Score total Persistent % subdermally total Persistent % intramuscularly , specific valuable indicator help u modify Botox dosage duration inject `` unknown '' subdermal bloodless space Aim 2 . Aim 2 12 month , use Botox , instead Gadolinium , demonstrate advantage ASIS device subdermally intramuscularly , particular 6 muscle group 60 Chronic Migraine adult . Given n't way detect Botox peripheral blood document Prolongation Botox Pharmacokinetically , Relative Prolongation Ability best possible way demonstrate subdermal bloodless space 's ability Botox . Although valuable , Relative Prolongation Ability Score Aim 1 n't absolutely required start Aim 2 . Hypothetically speak , subdermal bloodless space patient e.g. , Chronic Migraine somehow fail show prolongation half-life Gadolinium Aim 1 , still proceed primary interest therapeutic comparison Botox Aim 2 , term reduction Number Headache Days Baseline , adverse reaction .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Must history chronic migraine ( without aura ) accord criterion propose Headache Classification Committee International Headache Society least 3 month prior enrollment . Must able understand requirement study include maintain headache diary , sign informed consent . If take migraine preventive , must stable dose preventive medication least 3 month . Has headache disorder outside IHSdefined chronic migraine definition . Has evidence underlie pathology contribute headache . Has pathology salivary gland sialadenitis ( e.g . Sjogren 's syndrome , viral bacterial sialadenitis ) condition symptom would alter content saliva . Has medical condition may increase risk exposure Botox include diagnose myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis , significant disease might interfere neuromuscular function . Has profound atrophy weakness muscle target area injection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Subdermal bloodless space</keyword>
	<keyword>Subdermal injection</keyword>
	<keyword>injectable EMG needle</keyword>
	<keyword>electrical stimulation</keyword>
	<keyword>MRI Gadolinium</keyword>
	<keyword>Chronic Migraine</keyword>
	<keyword>intramuscular injection</keyword>
</DOC>